ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1702

Antiphospholipid Antibodies in Systemic Sclerosis: Prevalence and Clinical Significance?

Anjali Shetty1, Suncica Volkov1, Claudia Vergara2 and William Swedler3, 1Medicine/Rheumatology, University of Illinois at Chicago, Chicago, IL, 2Rheumatology, University of Illinois Chicago, Chicago, IL, 3Section of Rheumatology, University of Illinois at Chicago, Chicago, IL

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Antiphospholipid antibodies, interstitial lung disease and systemic sclerosis, Raynaud's phenomenon

  • Tweet
  • Email
  • Print
Session Information

Session Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics: Systemic Sclerosis, Diagnostic and Therapeutic Aspects

Session Type: Abstract Submissions (ACR)

Background/Purpose: Systemic Sclerosis (SSc) is an autoimmune disease characterized by collagen deposition and vascular changes of the skin and internal organs, leading ultimately to fibrosis.   Antiphospholipid (aPL) antibodies are immunoglobulins directed against negatively charged phospholipid-binding proteins mostly involved in blood coagulation.  It has been suggested that aPL antibodies including anticardiolipin (aCL) and anti-beta-2-glycoprotein I (aβ2GPI) antibodies may play a role in the pathogenesis of SSc related vascular impairment. This study investigates the prevalence of antiphospholipid antibodies including aCL and aβ2GPI antibodies in patients with systemic sclerosis.  We also evaluated a possible relationship between clinical findings in SSc including Raynaud’s phenomenon, digital ulcers, and interstitial lung disease, and the presence of aCL/ aβ2GPI antibodies. 

Methods:  A hundred patients who met the American College of Rheumatology classification criteria for systemic sclerosis were included in the study.  There were ten men and ninety women with a median age of 58 years.  Thirty-five percent had diffuse cutaneous SSc and 65 percent had limited cutaneous SSc.   Assessment of organ involvement to detect systemic complications of SSc included presence of Rayanud’s phenomenon, digital ulcers or pitting scars, and interstitial lung disease.  Interstitial lung disease was characterized by pulmonary fibrosis seen on high-resolution computed tomography or chest radiography, or occurrence of “velcro” crackles on auscultation, not due to another cause such as congestive heart failure.  Anticardiolipin IgG, IgM, and IgA and anti-beta-2-glycoprotein I IgG, IgM, and IgA antibodies were measured by enzyme-linked immunosorbent assay.  Clinical associations were measured using conditional and simple logistic regression models. 

Results: Twenty-seven percent of patients with systemic sclerosis were positive for either anticardiolipin or anti-beta-2-glycoprotein I (aβ2GPI) antibodies.  A positive association was found between the presence of anticardiolipin antibody and interstitial lung disease (p=0.038).  This association was maintained after adjusting for age, sex, and race (OR 2.765, 95% CI 1.038-7.368, p=0.0412). Anticardiolipin testing was not sensitive for predicting lung involvement with a sensitivity of 0.419, however, it had a high specificity at 0.789 for predicting lung involvement.  There was no predictive value found for testing aCL and aβ2GPI antibodies with regards to Raynaud’s phenomenon or digital ulcers. 

Conclusion: Our study showed a positive association with aCL antibodies and interstitial lung disease in patients with systemic sclerosis.  The use of aCL antibodies as a biomarker of pulmonary disease in SSc should be further explored.

 Table 1. Association of positive anticardiolipin and anti-beta-2-glycoprotein I antibody testing with clinical features in SSc patients.             

 

Raynauds phenomenon

Odds ratios (95% confidence intervals)

Digital Ulcers

Odds ratios (95% confidence intervals)

Interstitial Lung Disease

Odds ratios (95% confidence intervals)

Anticardiolipin antibody

OR 1.844

(0.175-19.427)

OR 1.387

(0.522-3.688)

OR 2.765

(1.038-7.368)

Anti-beta2-glycoprotein I antibody

OR 0.629

(0.033-12.012)

OR 3.427

(0.382-30.8)

OR 0.845

(0.076-9.398)

 


Disclosure:

A. Shetty,
None;

S. Volkov,
None;

C. Vergara,
None;

W. Swedler,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/antiphospholipid-antibodies-in-systemic-sclerosis-prevalence-and-clinical-significance/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies